High circulating levels of sHLA-E were also found in various cancer settings [44,45,46,47], which led to the development of a novel immune check point inhibitor targeting the HLA-E specific NKG2A inhibitor receptor, namely Monalizumab [47]. Here, KLRC1 is linked to cancer.